[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-358948-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-358948-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","identification-of-hspe1-as-a-new-actionable-cancer-vulnerability-leads-to-an-innovative-and-effective-combination-therapy-for-pancreatic-ductal-adenocarcinoma","Identification of HSPE1 as a new actionable cancer vulnerability leads to an innovative and effective combination therapy for pancreatic ductal adenocarcinoma","","Pancreatic ductal adenocarcinoma (PDAC) remains among the deadliest cancers, constrained by limited therapies and few druggable vulnerabilities. An unbiased in vivo tumor-selective genome-wide CRISPR loss-of-function screen identified the mitochondrial co-chaperone HSPE1 (Hsp10) as a tumor-promoting dependency. HSPE1 depletion impaired growth, survival, and tumor initiation across PDAC models, including patient-derived xenografts. Mechanistically, HSPE1 formed a dual, targetable survival network: with HSPD1 to control cell-cycle progression and apoptosis, and through an HSPD1-independent link to mitochondrial dynamics via the OPA1/OMA1 axis. Pharmacologic inhibition of the HSPD1/HSPE1 complex or the OPA1/OMA1 pathway suppressed tumors, and combined targeting produced synergistic antitumor activity and consistent incremental benefit over standard chemotherapies, supporting translational relevance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/identification-of-hspe1-as-a-new-actionable-cancer-vulnerability-leads-to-an-innovative-and-effective-combination-therapy-for-pancreatic-ductal-adenocarcinoma/358948/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/identification-of-hspe1-as-a-new-actionable-cancer-vulnerability-leads-to-an-innovative-and-effective-combination-therapy-for-pancreatic-ductal-adenocarcinoma/358948.png","ImageObject",300,407,{"name":42,"@type":43},"Rowan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What vulnerability did the in vivo CRISPR screen identify in PDAC?","Question",{"text":63,"@type":64},"The screen identified HSPE1 (Hsp10), a mitochondrial co-chaperone, as a previously unrecognized tumor-promoting dependency and actionable vulnerability in pancreatic ductal adenocarcinoma.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did HSPE1 affect PDAC cells at the mechanistic level?",{"text":68,"@type":64},"HSPE1 functioned as a central survival node by coordinating two parallel pathways: a canonical HSPD1-linked pathway regulating cell-cycle progression and apoptosis, and a separate mitochondrial-dynamics mechanism tied to the OPA1/OMA1 axis.",{"name":70,"@type":61,"acceptedAnswer":71},"What therapeutic strategy was tested and what were the results?",{"text":72,"@type":64},"Pharmacological inhibition of either the HSPD1/HSPE1 complex or the OPA1/OMA1 pathway suppressed tumor growth, while combined targeting produced robust synergistic antitumor activity and consistent incremental benefit alongside standard-of-care chemotherapy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},358948,1790197119,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","Boudreault etal. Molecular Cancer (2026) 25:62 Molecular Cancer  \n[https://doi.org/10.1186/s12943-026-02587-9](https://doi.org/10.1186/s12943-026-02587-9)  \nRESEARCH Open Access  \nIdentification of HSPE1 as a new actionable cancer vulnerability leads to an innovative and effective combination therapy for pancreatic ductal adenocarcinoma  \nJulien Boudreault1†, Shima Rahimirad1†, Ni Wang1, Gang Yan1, Leslie Chaltel Lima 1, Sophie Poulet1, Meiou Dai 1, Suhad Ali1 and Jean-Jacques Lebrun1*  \nAbstract  \nPancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest human malignancies, with limited therapeutic options and a lack of druggable vulnerabilities beyond a narrow set of oncogenic drivers. To identify cancer dependencies that are both essential in vivo and drug-tractable, we performed an unbiased genome-wide CRISPR loss-of-function screen under in vivo tumor-selective pressure. This approach revealed the mitochondrial co-chaperone HSPE1 (Hsp10) as a previously unrecognized, tumor-promoting dependency in PDAC. Genetic depletion of HSPE1 markedly impaired tumor growth, survival, and tumor-initiating capacity across multiple PDAC models in vitro and in vivo, including patient-derived xenografts. Mechanistically, HSPE1 functioned as a central survival node by engaging two parallel and targetable mitochondrial pathways. First, HSPE1 cooperated with its canonical partner HSPD1 to regulate cell-cycle progression, and apoptosis. Second, HSPE1 was functionally associated with mitochondrial dynamics, correlating with altered regulation of the OPA1/OMA1 axis, revealing an HSPD1-independent mechanism linking mitochondrial stress adaptation to cancer cell fitness. This dual signaling architecture exposes a previously unappreciated mitochondrial vulnerability selectively exploited by PDAC cells. Importantly, both HSPE1-regulated pathways were amenable to therapeutic targeting in vivo. Pharmacological inhibition of the HSPD1/HSPE1 complex or the OPA1/OMA1 pathway significantly suppressed tumor growth, while combined targeting produced robust synergistic antitumor activity in both cell line–derived and patient-derived PDAC models. Moreover, this combination strategy provides a modest yet consistent incremental benefit to standard-of-care chemotherapies, underscoring its translational relevance. Together, these findings establish HSPE1 as a bona fide cancer dependency uncovered through in vivo functional genomics, uncover a dual mitochondrial vulnerability, and provide a rational framework for combination therapy design. More broadly, this work highlights the power of in vivo CRISPR screening to directly inform therapeutic strategies and identifies mitochondrial stress adaptation as a promising and generalizable target in cancer.  \n†Julien Boudreault and Shima Rahimirad contributed equally to this work.  \n*Correspondence: Jean-Jacques Lebrun [jj.lebrun@mcgill.ca](jj.lebrun@mcgill.ca)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [h","cbCaih75RYEQ724P","https://ap.wps.com/l/cbCaih75RYEQ724P","pdf",4202809,26,"English","# Abstract\n## Introduction\n## Graphical Abstract","[{\"question\":\"What vulnerability did the in vivo CRISPR screen identify in PDAC?\",\"answer\":\"The screen identified HSPE1 (Hsp10), a mitochondrial co-chaperone, as a previously unrecognized tumor-promoting dependency and actionable vulnerability in pancreatic ductal adenocarcinoma.\"},{\"question\":\"How did HSPE1 affect PDAC cells at the mechanistic level?\",\"answer\":\"HSPE1 functioned as a central survival node by coordinating two parallel pathways: a canonical HSPD1-linked pathway regulating cell-cycle progression and apoptosis, and a separate mitochondrial-dynamics mechanism tied to the OPA1/OMA1 axis.\"},{\"question\":\"What therapeutic strategy was tested and what were the results?\",\"answer\":\"Pharmacological inhibition of either the HSPD1/HSPE1 complex or the OPA1/OMA1 pathway suppressed tumor growth, while combined targeting produced robust synergistic antitumor activity and consistent incremental benefit alongside standard-of-care chemotherapy.\"}]","Identification of HSPE1 as a new actionable cancer vulnerability leads to an innovative and effective combination therapy for pancreatic ductal adenocarcinoma | PDF",1790135685,66,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ecdc57f641f5f62b114e055cceeb74d7.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a995b77aed96de5935c6dd2779d7affd.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c1bdf7cabfbd10cb9a6ceb8d9e17c7c.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6475901d9e2ee9c013bf9dc84880230b.webp",980,1306]